Ambrx's pipeline includes ARX788, ARX517, ARX305, and other clinical and preclinical programs designed to optimize efficacy, safety, and ease of use. These programs focus on developing next-generation antibody drug conjugates, bispecifics, targeted immuno-oncology therapies, novel cytokines, and long-acting therapeutic peptides for metabolic and cardiovascular disease. Ambrx's proprietary expanded genetic code technology platform allows incorporating synthetic amino acids into proteins within living cells, which enables the development of a novel class of engineered precision biologics.